NCT05954169View on ClinicalTrials.gov

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions

Hyperuricemia

Interventions

DRUG

SHR4640

SHR4640 single-dose

Trial Locations (1)

511447

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY